Who’s Driving the Craze for Ozempic, Other Weight Loss Drugs

Extensive media coverage and high obesity rates are fueling interest in prescription weight loss drugs, writes deputy head of industry intelligence Nicki Zink.

By Nicki Zink – October 25, 2023


  • 28% of U.S. adults said they are interested in taking prescription GLP-1 drugs like Ozempic, Mounjaro or Wegovy for weight loss, a share relatively consistent with August and April surveys.
  • Consumers who have heard “a lot” about the drugs, have weight-related health conditions or have higher incomes are most likely to be interested in taking the medications.
  • The impacts of weight loss drugs on the health industry are clear, but other sectors, like food and retail, are likely to feel the effects of changing consumer preferences. Brands that create products and services to help support a more health-conscious consumer will be best-positioned to weather disruption from Ozempic or future weight loss drug innovations.